Medical Economics March 18, 2025
Investment will support the expansion of its FDA-approved therapy designed to improve upper extremity function in chronic ischemic stroke survivors.
MicroTransponder Inc. announced the completion of a $65 million Series F financing round. The investment will support the expansion of its FDA-approved Vivistim Paired VNS System, an innovative therapy designed to improve upper extremity function in chronic ischemic stroke survivors.
The funding round was led by US Venture Partners (USVP) and included participation from existing investors such as Osage University Partners, Action Potential Venture Capital, GPG Ventures, The Vertical Group, and Exceller Hunt Ventures. Two new investors, Gilde Healthcare and Longitude Capital, also joined the round.
“The MicroTransponder executive leadership team is building the company in a very thoughtful way...
Today's Sponsors
Today's Sponsor